bioAffinity Technologies Executes 1-for-15 Reverse Split to Regain Nasdaq Compliance

summarizeSummary

bioAffinity Technologies announced a 1-for-15 reverse stock split effective August 21, 2026, to regain compliance with Nasdaq's $1 minimum bid price requirement. The split will reduce outstanding shares to approximately 592,373 and is expected to lift the share price above the threshold.

check_boxKey Events · Corporate Governance and Compliance · BIAF

• 1-for-15 Reverse Split Executed

  Board approved a 1-for-15 reverse split, effective 4:01 p.m. ET on August 21, 2026. Trading on a split-adjusted basis begins August 24, 2026.

• Post-Split Share Count

  Immediately after the split, the company will have approximately 592,373 shares of common stock outstanding, down from roughly 8.9 million pre-split.

• Nasdaq Compliance Effort

  The reverse split is primarily intended to bring the company into compliance with Nasdaq's $1 minimum bid price requirement, following a delisting notice received July 31, 2026.

• New CUSIP Number

  The common stock has been assigned a new CUSIP number (09076W406), while the publicly traded warrants (BIAFW) retain their existing CUSIP.

auto_awesomeAnalysis · BIAF · Industrial Applications And Services

The board selected a 1-for-15 reverse split ratio from the range approved by stockholders in April, effective August 21, 2026. This is a direct response to the Nasdaq delisting notice received July 31 for failing the $1 minimum bid price rule. The reverse split will reduce outstanding shares from roughly 8.9 million to about 592,373, mechanically lifting the share price to approximately $5.81 based on today's $0.387 close. While the split itself does not change market capitalization or ownership percentages, it is a critical step to avoid delisting and maintain Nasdaq listing. The company's going concern warning and cash runway ending this month make the listing status especially important for continued access to capital.